Nuvelo Announces Publication of Preclinical Data From Wnt Therapeutics Program
June 05 2008 - 7:30AM
PR Newswire (US)
SAN CARLOS, Calif., June 5 /PRNewswire-FirstCall/ -- Nuvelo, Inc.
(NASDAQ:NUVO) today announced the publication of preclinical data
from the company's Wnt Therapeutics program showing that the
R-spondin family of proteins activate the Wnt pathway, a signaling
pathway that is critical for cell growth and differentiation during
homeostasis and pathogenesis. The R-spondin proteins also amplified
the activity of Wnt proteins, and modulated the Wnt pathway by a
common mechanism. The study, entitled "R-spondin Family Members
Regulate the Wnt Pathway by a Common Mechanism," is published in
the June issue of Molecular Biology of the Cell (MBC). "This study
reinforces the therapeutic potential of our R-spondin family of
proteins in our Wnt therapeutics program, which target a range of
indications where cell regeneration and differentiation are
important to disease processes, including gastrointestinal disease,
bone disorders and wound healing," said Dr. Ted W. Love, chairman
and chief executive officer of Nuvelo. "We are on track to begin
two Phase 1 trials with NU206, the lead candidate in our Wnt
Therapeutics program, in the second and third quarters of this
year. We are also continuing to assess the therapeutic potential of
other secreted proteins in the R-spondin family." About R-spondin
secreted proteins The R-spondin (Rspo) family of secreted proteins
are the first biologic agents that can be used to enhance
endogenous Wnt signaling in vivo, and provide therapeutic potential
in diseases that are dependent on the Wnt pathway for maintenance
of tissue integrity and tissue repair. Rspo proteins are novel
regulators of the Wnt pathway and were first identified by Nuvelo
as potent gastrointestinal mitogens in transgenic mice (1). About
Nuvelo Nuvelo, Inc. is dedicated to improving the lives of patients
through the discovery, development and commercialization of novel
drugs for acute cardiovascular disease, cancer and other
debilitating medical conditions. Nuvelo's development pipeline
includes NU172, a direct thrombin inhibitor in Phase 1 development
for use as a potential short-acting anticoagulant during medical or
surgical procedures; and preclinical candidate NU206, a Wnt pathway
modulator for the potential treatment of chemotherapy/radiation
therapy-induced mucositis and inflammatory bowel disease. In
addition, Nuvelo is pursuing research programs in leukemia and
lymphoma therapeutic antibodies and Wnt signaling pathway
therapeutics to further expand its pipeline and create additional
partnering and licensing opportunities. Information about Nuvelo is
available at our website at http://www.nuvelo.com/ or by phoning
650-517-8000. This press release contains "forward-looking
statements," which include statements regarding the timing,
progress and anticipated completion of Nuvelo's clinical stage and
research programs, the anticipated availability of top-line data,
and the potential benefits that patients may experience from the
use of our clinical stage compounds, which statements are hereby
identified as "forward-looking statements" for purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of
1995. Such statements are based on our management's current
expectations and involve risks and uncertainties. Actual results
and performance could differ materially from those projected in the
forward- looking statements as a result of many factors, including,
without limitation, uncertainties relating to drug discovery and
the regulatory approval process; clinical development processes;
enrollment rates for patients in our clinical trials; changes in
relationships with strategic partners and dependence upon strategic
partners for the performance of critical activities under
collaborative agreements; and the impact of competitive products
and technological changes. These and other factors are identified
and described in more detail in Nuvelo's filings with the SEC,
including without limitation Nuvelo's quarterly report on Form 10-Q
for the quarter ended March 31, 2008 and subsequent filings. We
disclaim any intent or obligation to update these forward-looking
statements. (1) Kim et al. (2005) Mitogenic influence of human
R-Spondin1 on the intestinal epithelium. Science 309. DATASOURCE:
Nuvelo, Inc. CONTACT: Lee Bendekgey, SVP and Chief Financial
Officer of Nuvelo, +1-650-517-8358, ; or Nicole Foderaro of
WeissComm Partners, +1-415-946-1058, , for Nuvelo, Inc. Web site:
http://www.nuvelo.com/
Copyright
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From Jul 2023 to Jul 2024